Vimarsana
Biggest News Aggregation in the World

Molecular Screening News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Molecular Screening. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Molecular Screening Today - Breaking & Trending Today

Wistar scientists uncover a key mechanism as to how p53 suppresses tumors - Vimarsana News

Wistar scientists uncover a key mechanism as to how p53 suppresses tumors

The p53 gene is one of the most important in the human genome: the only role of the p53 protein that this gene encodes is to sense when a tumor is forming and to kill it.

The Wistar Institute: Wistar Scientists Discover Innate Tumor Suppression Mechanism - Vimarsana News

The Wistar Institute: Wistar Scientists Discover Innate Tumor Suppression Mechanism

Findings could benefit African Americans who possess a specific genetic variant of p53PHILADELPHIA, PA, May 04, 2023, a journal of the American Association for Cancer Research, researchers at The Wistar

Avantor to acquire liquid handling manufacturer Ritter for $1B - Vimarsana News

Avantor to acquire liquid handling manufacturer Ritter for $1B

Avantor has entered into an agreement to acquire Ritter and its affiliates for approximately $1.05 billion in an all-cash transaction.

UNSW Sydney and the Garvan Institute of Medical Research researchers will lead the program, thanks to a $3.75 million grant from the Cancer Institute NSW - Vimarsana News

UNSW Sydney and the Garvan Institute of Medical Research researchers will lead the program, thanks to a $3.75 million grant from the Cancer Institute NSW

Share A national clinical trial program will test promising new targeted therapies for pancreatic cancer, one of the deadliest forms of cancers of which more than 3000 cases are diagnosed annually in Australia. The clinical trial program (MoST–P), led by researchers and clinicians at UNSW and the Garvan Institute, will provide patients with access to either targeted therapies matched to the genomic signature of their individual tumour, or targeted to the tumour environment. UNSW Dean of Medicine & Health, Professor Vlado Perkovic said the grant could lead to better outcomes for pancreatic c...

Pancreatic cancer clinical trial program to target genome and scar tissue - Vimarsana News

Pancreatic cancer clinical trial program to target genome and scar tissue

UNSW Sydney and the Garvan Institute of Medical Research researchers will lead the program, thanks to a $3.75 million grant from the Cancer Institute...